Zerbit, J.; Detroit, M.; Meyer, A.; Decroocq, J.; Deau-Fischer, B.; Deschamps, P.; Birsen, R.; Mondesir, J.; Franchi, P.; Miekoutima, E.;
et al. Patients with Hematological Malignancies Treated with T-Cell or B-Cell Immunotherapy Remain at High Risk of Severe Forms of COVID-19 in the Omicron Era. Viruses 2022, 14, 2377.
https://doi.org/10.3390/v14112377
AMA Style
Zerbit J, Detroit M, Meyer A, Decroocq J, Deau-Fischer B, Deschamps P, Birsen R, Mondesir J, Franchi P, Miekoutima E,
et al. Patients with Hematological Malignancies Treated with T-Cell or B-Cell Immunotherapy Remain at High Risk of Severe Forms of COVID-19 in the Omicron Era. Viruses. 2022; 14(11):2377.
https://doi.org/10.3390/v14112377
Chicago/Turabian Style
Zerbit, Jeremie, Marion Detroit, Antoine Meyer, Justine Decroocq, Benedicte Deau-Fischer, Paul Deschamps, Rudy Birsen, Johanna Mondesir, Patricia Franchi, Elsa Miekoutima,
and et al. 2022. "Patients with Hematological Malignancies Treated with T-Cell or B-Cell Immunotherapy Remain at High Risk of Severe Forms of COVID-19 in the Omicron Era" Viruses 14, no. 11: 2377.
https://doi.org/10.3390/v14112377
APA Style
Zerbit, J., Detroit, M., Meyer, A., Decroocq, J., Deau-Fischer, B., Deschamps, P., Birsen, R., Mondesir, J., Franchi, P., Miekoutima, E., Guerin, C., Batista, R., Bouscary, D., Willems, L., & Vignon, M.
(2022). Patients with Hematological Malignancies Treated with T-Cell or B-Cell Immunotherapy Remain at High Risk of Severe Forms of COVID-19 in the Omicron Era. Viruses, 14(11), 2377.
https://doi.org/10.3390/v14112377
